'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injury.
acute kidney injury
acute tubulointerstitial nephritis
fluindione
immune checkpoint inhibitors
proton pump inhibitors
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
07
06
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
The introduction of immune checkpoint inhibitors (ICI) has resulted in significant improvement in cancer care, but has been accompanied by the occurrence of immune-related adverse events (irAEs). Also, kidney irAEs have been reported, and the most frequent one is acute tubulointerstitial disease which impacts renal and overall prognosis. There is an unmet need to stratify renal risk in oncologic patients, to allow individualized monitoring and therefore, early detection of ICI-related acute kidney injury (ICI-AKI). Although risk factors for ICI-AKI have been described in previous case-control studies, where 'cases' were ICI-AKI patients and 'controls' ICI-treated patients without AKI, there is limited epidemiologic knowledge concerning patients developing different irAEs. In this issue of the
Identifiants
pubmed: 36158160
doi: 10.1093/ckj/sfac161
pii: sfac161
pmc: PMC9494511
doi:
Types de publication
Editorial
Langues
eng
Pagination
1803-1806Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Case Rep Nephrol. 2016;2016:9818195
pubmed: 27127666
Front Immunol. 2021 Jan 21;11:624547
pubmed: 33552089
Front Immunol. 2020 Oct 08;11:574271
pubmed: 33162990
Front Immunol. 2021 Oct 27;12:716317
pubmed: 34777340
Nephrol Dial Transplant. 2012 Apr;27(4):1554-8
pubmed: 21931126
Immunotherapy. 2021 Dec;13(17):1407-1417
pubmed: 34709083
J Am Soc Nephrol. 2020 Feb;31(2):435-446
pubmed: 31896554
Kidney Int. 2020 Jan;97(1):62-74
pubmed: 31685311
Nat Med. 2022 Feb;28(2):353-362
pubmed: 35027754
Oncoimmunology. 2021 Jul 21;10(1):1929727
pubmed: 34350061
Cancer Cell. 2022 May 9;40(5):509-523.e6
pubmed: 35537412
N Engl J Med. 2009 Jul 9;361(2):211-2
pubmed: 19587352
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33849926
Front Immunol. 2021 May 10;12:619147
pubmed: 34040602
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34625513
Am J Nephrol. 2017;45(2):160-169
pubmed: 28076863
Clin Nephrol. 2006 Dec;66(6):455-8
pubmed: 17176918
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Kidney360. 2020 Feb 11;1(3):158-161
pubmed: 35368633